Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE Trial: Equol for Arterial Stiffness and Cognition
NCT05741060Phase 2Active, not recruiting
- Start
- Jun 2023
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of s-equol in arterial stiffness, White matter lesions (WML), No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.. Started Jun 2023; status: active, not recruiting.
02
Drugs
s-equol
03
Conditions
arterial stiffnessWhite matter lesions (WML)No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT05741060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741060.